|
15 Oct 2018 |
Shurgard Self Storage makes debut on Euronext Brussels |
|
 |
Pioneer of self-storage in Europe raises €575 million, making it the second largest newly-listed company to join Euronext Brussels over the last decade
Brussels, 15 October 2018 – Shurgard Self Storage SA (“Shurgard”, ticker symbol: SHUR) today began trading on Euronext Brussels (Compartment A) with an initial market capitalisation of €2.04 billion.
Shurgard is the largest owner and operator of self-storage centers (stores) in Europe in terms of number of stores and net rentable square meters. Shurgard commenced operations in 1995 and is one of the pioneers of the self-storage concept in Europe. In total, its network of 229 stores comprises approximately 1.2 million net rentable square meters and serves more than 150,000 customers in the Netherlands, France, Sweden, the United Kingdom, Belgium, Germany and Denmark.
With an Offer Price at €23 per share, Shurgard’s total offering size amounts to €575 million. With a total of 88,935,681 shares admitted to trading, Shurgard has an initial market capitalisation before opening of €2.04 billion.
Marc Oursin, CEO of Shurgard, said: “With the ringing of the Euronext Brussels bell, we are starting a new chapter in our company’s history. Still, our core value will always remain the same: to provide the best storage experience for our customers and to further strengthen our platform of self-storage centers with growth across the 7 countries where we operate.”
To mark Shurgard’s first trading day, Marc Oursin, CEO, rang the bell to open the markets in Brussels today.
| Attachments | | Available Languages |
|---|
| Download press release | | en |
|
|
08 Oct 2018 |
Medincell lists on Euronext Paris |
|
|
€30 million raised; market capitalisation €144 million
Paris – 8 October 2018 – Euronext today welcomed MedinCell, a pharmaceutical technology company that develops injectable drug delivery solutions, to listing in compartment C of Euronext Paris.
Based in Jacou, near Montpellier in southern France, MedinCell is dedicated to achieving significant gains in the efficiency of drug therapies. The two most advanced products in its pipeline, designed to treat schizophrenia and post-operative orthopedic pain, respectively, are now in Phase III and Phase II clinical trials in the United States. Its seven other products treat a range of conditions including depression, chronic pain and contraception—all areas where MedinCell’s patented BEPO® technology is likely to change conditions fundamentally.
MedinCell (ticker code: MEDCL) was listed on 8 October 2018 through the admission to trading of 19,878,372 shares making up its capital, including 4,137,931 new shares issued through a Global Offering[1] before potential exercise of the over-allotment option and 1,258,841 shares issued in exchange for convertible bonds.
The offering price was set at €7.25 per share. Market capitalisation on the day of listing was around €144 million, and the operation raised a total of €30 million.
At the listing ceremony, Christophe Douat, Chairman of MedinCell’s Executive Board, said: “Today’s listing is a milestone for MedinCell. It confirms the expertise and tenacity of the entire MedinCell team, and illustrates the strength of our approach, in which all of our staff members are either already shareholders or will have that opportunity. This is one key to our success—a success that includes two products already in Phase II and III clinical trials in the United States, with ten more in the pipeline. The funds we’ve raised will enable us to expand our portfolio and increase our impact on global health. I would like to take this opportunity to thank all our team members who have been working hard to this end, as well as the new shareholders who have joined us and who share our goals, including our vision of harnessing pharmaceuticals to serve human well-being, and our commitment to a better world.”
[1] The Global Offering was made up of a Public Offering that included an Open Price Offer (OPO) in France and a Global Placement with institutional investors in France and other countries.
About MedinCell
MedinCell is a pharmaceutical company developing a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients that are already known and marketed. Based on controlled, long-acting release of active pharmaceutical ingredients, MedinCell makes medical treatments more efficient by improving patient adherence to medical prescriptions and by significantly reducing the quantity of medication required to treat one-off and chronic conditions. BEPO® technology ensures consistent, reliable delivery of a drug at the optimum therapeutic dose for several days, weeks or months, starting from a small subcutaneous or local injection and deposit that is fully bioresorbable. Based in Montpellier, MedinCell currently employs approximately 100 people representinq over 25 different nationalities.
| Attachments | | Available Languages |
|---|
| Download press release | | en | fr |
|
|
04 Oct 2018 |
Euronext Announces Volumes for September 2018 |
|
|
Amsterdam, Brussels, Dublin, Lisbon, London and Paris – 4 October 2018 – Euronext, the leading pan-European exchange in the Eurozone, today announced trading volumes for September 2018.
Cash trading
In September 2018, the average daily transaction value on the Euronext cash order book stood at €8,346.0 million, up +11.3% compared to September 2017 and up +34.9% from the previous month.
On 21 September 2018, Euronext daily volume reached a new record for the year, at €23,497 million, representing the most active day since 2010. The average daily transaction value on the ETF order book[1] was €216 million, up +2.6% compared to September 2017 and up +22.8% from the previous month. At the end of September 2018, 1,125 ETFS were listed on Euronext compared to 1,048 at the end of December 2017.
Derivatives trading
In September 2018, the overall average daily volume on derivatives reached 574,984 contracts, up +14.6% compared to September 2017 and up +11.3% compared to the previous month. In detail:
- the average daily volume on equity index derivatives reached 218,213 contracts, up +7.9% compared to September 2017 and up +15.1% from the previous month,
- the average daily volume on individual equity derivatives reached 307,800 contracts, up +19.9% compared to September 2017 and up +24.7% from the previous month. September also saw the most active day for individual equity futures since 2012, with 144,674 lots traded on 13 September,
- the average daily volume on commodity derivatives reached 48,971 contracts, up +14.8% compared to September 2017 and down −38.8% from the previous month.
At the end of September 2018, the overall average daily volume on Euronext derivatives stood at 579,608 contracts (+5.1% compared to the end of September 2017) and open interest was up at 18,468,073 contracts (+9.3% compared to the end of September 2017).
FX spot trading
In September 2018, the average daily volume on the spot foreign exchange market of FastMatch, operating as a Euronext company since August 2017, stood at $18,646 million, down −10.7% compared to September 2017 and down −4.2% from the previous month.
Listings
In September 2018, Euronext welcomed the listing of Italy-based company MyBest Group and Spanish real-estate investment fund Barings Core, which together raised €2.45 million. In addition, €116.3 billion was raised on Euronext in bonds and €2.7 billion in follow-on equity.
[1] From January 2018, volumes on ETFs are only measured on order book activity due to low revenue impact of off-book activity. Based on the previous presentation, activity is €290 million, up +37.8% compared to September 2017.
| Attachments | | Available Languages |
|---|
| Download the full press release | | en |
|
|
02 Oct 2018 |
Update on the integration of Euronext Dublin |
|
|
Amsterdam, Brussels, Dublin, Lisbon, London and Paris – 2 October 2018 – Euronext today announced an update on the integration of Euronext Dublin, of which Euronext completed the acquisition on 27 March 2018.
- Migration to Optiq® for Euronext Dublin in February 2019
The migration of Euronext Dublin’s Cash Market to Euronext’s trading platform Optiq® is now planned in February 2019, subject to regulatory approval.
The migration to Optiq®, Euronext’s proprietary trading platform, will allow Euronext Dublin trading members and investors to benefit from access to trading across all cash equity asset classes available on Euronext’s pan-European exchanges. Euronext and Deutsche Börse will work together actively to ensure a smooth transition.
- Upgraded cost synergies targets
As a result of the first successful integration steps, Euronext has identified additional cost-saving opportunities, and now expects to deliver €8 million (vs €6 million announced at the time of acquisition) in pre-tax run-rate cost synergies. As part of the integration, total costs of €14 million (vs €9 million announced at the time of acquisition) will be incurred in the first years of integration.
- Signing of a termination agreement with Deutsche Börse for the migration of Euronext Dublin to Optiq®
Euronext has signed an agreement for the early termination of the trading services contract provided by Deutsche Börse AG to the Irish Stock Exchange (now operating as Euronext Dublin), initially due on December 2021. This agreement will contribute to approximately 50% of the announced €8 million in cost synergies. Furthermore, Euronext will recognise a €4 million impact from this settlement as an exceptional P&L expense in Q3 2018.
| Attachments | | Available Languages |
|---|
| Download full press release | | en |
|
|
21 Sep 2018 |
Over 100 new companies join Euronext’s Techshare programme, expanding to four new countries |
|
|
- Euronext kicks off its fourth annual capital markets training programme for non-listed companies, expanding to Germany, Italy, Spain and Switzerland
- TechShare is the only dedicated programme for European technology companies focused on IPOs
- Total number of companies selected this year has quadrupled since the introduction of the programme
Amsterdam, Brussels, Frankfurt, Madrid, Milan, Munich, Lisbon, Paris and Zurich – 21 September 2018
Euronext, the leading pan-European exchange in the Eurozone, today launches its fourth session of TechShare, the only European programme for non-listed companies dedicated to IPOs. Benefitting from a cohort of fast-growing European tech companies, the programme is an educational network designed to help these high-potential businesses understand the role of capital markets and how they can help them reach the next stage of their growth.
For the first time, Euronext has decided to include companies from outside Euronext’s core markets, with participants from Germany, Italy, Spain and Switzerland.[1] This decision follows the opening of new representative offices in these countries 12 months ago and demonstrates the potential and dynamism of European companies in the tech sector.
<
The number of companies participating has also increased significantly with 135 companies in 2018 compared with 30 companies in 2015, representing a four-fold increase in only three years.
The companies taking part in the programme represent the vibrancy and diversity of the technology world, spanning a range of sectors driving the technology revolution, including biotech, software, medtech, electronics, hardware, cleantech, e-commerce and fintech. On average, participants generate annual revenues of over €10 million, and employ c.100 staff. They are also at increasingly mature stage of growth as two-thirds are venture capital-backed and they have each raised around €15 million in capital.
Euronext will support participating companies through academic and practical expertise, including coaching. Two core sessions will be held: one in September in Paris at Europe’s leading business school HEC, and a second one in March 2019 aimed at supporting the long-term vision of the business.
In addition, tailor-made coaching sessions will be held in each country throughout the year. They will be led by around 80 expert partners recruited by Euronext from a wide range of areas to generate unique networking opportunities, including banking, law and audit, financial communications, technology and research.
Stéphane Boujnah, CEO and Chairman of the Managing Board of Euronext, said: “Europe is brimming with highly innovative tech companies that have reached a critical stage in their growth. After several rounds of financing, they are now looking for better access to capital. To pursue their objectives, they also need focused support and the infrastructure that an efficient pan-European market can provide. This is precisely what we are offering at Euronext through TechShare and our trading platform. Together with our partners, we are proud to bring together such a diverse and stellar range of participants – companies that I am confident will help power the European economy of tomorrow.”
Since launching in 2015, TechShare has helped four French companies access capital markets: Osmozis, Balyo, Theranexus and Oxatis.
Europe’s tech sector at a glance (see appendix)
Learn more about the businesses taking part in this year’s session with the TechShare press kit
Euronext would like to thank the partners of its programme
[1] The new class has a total of 135 companies across Europe: 14 come from Belgium, 39 from France, 23 from Germany, 11 from Italy, 18 from the Netherlands, 9 from Portugal, 9 from Spain, and 12 from Switzerland.
| Attachments | | Available Languages |
|---|
| Download press release | | en |
| Europe’s tech sector at a glance | | en |
| Press kit | | en |
|
